ROTE WILLIAM E. — SEC Form 4 filings
SEC reporting owner CIK 1698262. 13 Form 4 filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-01-25 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 18 legs across 12 filings — 324,356 shares, $16,952,488 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 27.
- Largest priced transaction: sale of 65,104 shares @ $63.12 ($4,109,397) in Travere Therapeutics, Inc., filed 2026-09-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | Chief Research Officer | 13 | — | 18 legs · 324,356 sh · $16,952,488 | 27 |
Form 4 filings — ROTE WILLIAM E.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 39,000 @ $25.25 · Option exercise (M): 39,650 @ $17.96 · Sale (S): 63,907 @ $61.99 · Sale (S): 29,021 @ $62.66 · Sale (S): 3,000 @ $63.65 · Sale (S): 270 @ $65.31 · +10 more | EDGAR |
| 2026-05-06 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 4,250 @ $0 · Sale (S): 2,763 @ $43.95 · Grant/award (A): 8,500 (derivative) @ $0 · Option exercise (M): 4,250 (derivative) @ $0 | EDGAR |
| 2026-04-23 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 9,100 @ $39.09 | EDGAR |
| 2026-04-15 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 14,000 @ $0 | EDGAR |
| 2026-02-03 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 20,090 @ $0 · Sale (S): 12,446 @ $32.87 · Grant/award (A): 53,570 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 60,000 @ $20.61 · Sale (S): 60,000 @ $40.10 · Option exercise (M): 60,000 (derivative) @ $0 | EDGAR |
| 2025-05-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 4,920 · Sale (S): 3,198 @ $21.05 · Option exercise (M): 4,920 (derivative) @ $0 | EDGAR |
| 2025-02-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 8,000 · Sale (S): 5,200 @ $23.53 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 21,500 @ $0 · Sale (S): 8,951 @ $19.78 · Grant/award (A): 58,000 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 2,437 @ $19.46 | EDGAR |
| 2024-09-09 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,750 @ $0 · Sale (S): 4,387 @ $11.52 | EDGAR |
| 2024-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 25,000 @ $0 · Sale (S): 2,174 @ $8.53 · Sale (S): 2,590 @ $8.86 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2024-01-25 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 2,062 @ $8.96 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1698262 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →